09
Apr
With the current all-oral second generation direct-acting antiviral agents, over 95?% of treated patients can achieve SVR with an excellent safety profile [14C29]. Despite substantial gains in treating HCV with these new highly effective antiviral regimens, there are a number of barriers which still exist [30C34]. Mid-Atlantic and 1 Southeast). Of the screened populace, 10 individuals (0.5?%) were HCV AB-positive. HCV RNA testing was performed in 90?% (9/10) of HCV AB-positive individuals. Of those, 44.4?% (4/9) were HCV RNA-positive, and all 4 (100?%) were linked to caregiver. Compared to HCV AB negative subjects, HCV AB-positive individuals tended to be black…